UNITED STATES: Costs and Effectiveness of Partner Counseling and Referral Services with Rapid Testing for HIV in Colorado and Louisiana, United States

Important note: Information in this article was accurate in 2009. The state of the art may have changed since the publication date.

UNITED STATES: Costs and Effectiveness of Partner Counseling and Referral Services with Rapid Testing for HIV in Colorado and Louisiana, United States

Sexually Transmitted Diseases Vol. 36; No. 10: P. 637-641 (10..09) - Wednesday, November 04, 2009
Ram K. Shrestha; Elin B. Begley; Angela B. Hutchinson; Stephanie L. Sansom; Binwei Song; Kelly Voorhees; Amy Busby; Jack Carrel; Samuel Burgess

The researchers assessed the costs and effectiveness of partner counseling and referral services (PCRS) with rapid HIV testing in Colorado and Louisiana between April 2004 and January 2006. In Colorado, PCRS is provided to index patients and partners statewide. In Louisiana, PCRS is provided to those in Baton Rouge and New Orleans. The authors obtained program costs for personnel, travel, utilities, supplies, equipment, and facility space. Key effectiveness measures were the number of partners tested and the number of partners informed of a new HIV diagnosis after rapid testing.

Colorado's efforts identified a yearly average of 328 index patients and 253 partners; 43 partners underwent testing. Louisiana identified an annual average of 81 index patients and 138 partners; 83 partners underwent testing. Among partners tested, the rate of those previously undiagnosed was 6.6 percent in Colorado and 9.9 percent in Louisiana. The average costs per partner tested and per partner informed of a new HIV diagnosis were $1,459 and $22,243 in Colorado; the costs in Louisiana were $714 and $7,231.

"Program costs varied by location," the authors concluded. "Our analysis helps program managers and health care providers to understand the resources needed for implementing the PCRS in diverse settings."
091104
AD091897

Copyright © 2009 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from the Elton John AIDS Foundation, National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.